Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer
Background Long non‐coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer‐associated lncRNAs has been listed via RNA‐seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47,...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2018-08, Vol.78 (11), p.812-818 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 818 |
|---|---|
| container_issue | 11 |
| container_start_page | 812 |
| container_title | The Prostate |
| container_volume | 78 |
| creator | Bayat, Hamid Narouie, Behzad Ziaee, Seyed‐Amir Mohsen Mowla, Seyed Javad |
| description | Background
Long non‐coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer‐associated lncRNAs has been listed via RNA‐seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities to discriminate prostate tumors from benign prostate hyperplasia (BPH).
Methods
Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses. The expression of candidate lncRNAs was assessed by the real‐time PCR technique.
Results
Our data revealed that the expression levels of PRCAT17.3 (P |
| doi_str_mv | 10.1002/pros.23538 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2027588359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2057900982</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3578-a93e3c33ea67f18a3c483cfee9ee863e104cd0be455bb5eb1019d1a0422ff5063</originalsourceid><addsrcrecordid>eNp9kcFqFTEUhoMo9lrd-AAScCOlcz1JJneSZSnWCsWWWtdDJnNSU-Ym12SGcnfiE_iMPklznWqhC1fhJx__-c_5CXnNYMkA-PtNinnJhRTqCVkw0E0FUMunZAG8gapmotkjL3K-ASg48Odkj-tVw5TSC_Lz6jbSIYZrGmL4_eOXjb0v4vLzUT6kF8makTVLQU3oZyXUIbVxGnqKznnrMYzDlvY-2-TXPpgRaYfBXwe6SzXu9LftBtNmMNkb6lJcP_xYEyyml-SZM0PGV_fvPvl68uHq-LQ6O__46fjorLJCNqoyWqCwQqBZNY4pI2ythHWIGlGtBDKobQ8d1lJ2ncSOAdM9M1Bz7pyEldgn72bfMv_7hHls1yU2DoMJGKfc8nIuqZSQuqBvH6E3cUqhpCuUbDSAVrxQBzNly0I5oWs35QgmbVsG7a6Zdrdp-6eZAr-5t5y6Nfb_0L9VFIDNwK0fcPsfq_bi8vzLbHoHYZaakw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2057900982</pqid></control><display><type>article</type><title>Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer</title><source>Wiley Online Library All Journals</source><creator>Bayat, Hamid ; Narouie, Behzad ; Ziaee, Seyed‐Amir Mohsen ; Mowla, Seyed Javad</creator><creatorcontrib>Bayat, Hamid ; Narouie, Behzad ; Ziaee, Seyed‐Amir Mohsen ; Mowla, Seyed Javad</creatorcontrib><description>Background
Long non‐coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer‐associated lncRNAs has been listed via RNA‐seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities to discriminate prostate tumors from benign prostate hyperplasia (BPH).
Methods
Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses. The expression of candidate lncRNAs was assessed by the real‐time PCR technique.
Results
Our data revealed that the expression levels of PRCAT17.3 (P < 0.0001) and PRCAT38 (P < 0.0002) were significantly upregulated in human prostate cancer tissues, compared to BPH ones. Moreover, the altered expression was much higher for PRCAT17.3 (∼2000 folds) than PRCAT38 (∼50 folds). In contrast, the expression of Cat2184.4 showed a significant down‐regulation in tumor samples (P < 0.0001), compared to BPH ones. While the expression level of PRCAT47 was increased in cancer samples, the changes were not statistically significant. In discriminating prostate tumors from BPH samples, Prcat17.3 (AUC‐ROC, 0.927) demonstrated a better diagnostic efficacy than Prcat38 (AUC‐ROC, 0.778). Moreover, real‐time RT‐PCR analyses on urine samples of prostate cancer patients revealed that prcat17.3 level is significantly elevated, (P < 0.0197; AUC‐ROC value of 0.72), compared to that of BPH patients.
Conclusion
We introduce here two novel lncRNAs with a potential application in diagnosis of prostate cancer.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.23538</identifier><identifier>PMID: 29671889</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Benign ; biomarker ; BPH ; Data processing ; Genital diseases ; Hyperplasia ; lncRNA ; PRCAT17.3 ; Prostate cancer ; Ribonucleic acid ; RNA ; Statistical analysis ; Tumors ; Urine</subject><ispartof>The Prostate, 2018-08, Vol.78 (11), p.812-818</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3578-a93e3c33ea67f18a3c483cfee9ee863e104cd0be455bb5eb1019d1a0422ff5063</citedby><cites>FETCH-LOGICAL-c3578-a93e3c33ea67f18a3c483cfee9ee863e104cd0be455bb5eb1019d1a0422ff5063</cites><orcidid>0000-0003-2657-5438</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.23538$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.23538$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29671889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bayat, Hamid</creatorcontrib><creatorcontrib>Narouie, Behzad</creatorcontrib><creatorcontrib>Ziaee, Seyed‐Amir Mohsen</creatorcontrib><creatorcontrib>Mowla, Seyed Javad</creatorcontrib><title>Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Background
Long non‐coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer‐associated lncRNAs has been listed via RNA‐seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities to discriminate prostate tumors from benign prostate hyperplasia (BPH).
Methods
Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses. The expression of candidate lncRNAs was assessed by the real‐time PCR technique.
Results
Our data revealed that the expression levels of PRCAT17.3 (P < 0.0001) and PRCAT38 (P < 0.0002) were significantly upregulated in human prostate cancer tissues, compared to BPH ones. Moreover, the altered expression was much higher for PRCAT17.3 (∼2000 folds) than PRCAT38 (∼50 folds). In contrast, the expression of Cat2184.4 showed a significant down‐regulation in tumor samples (P < 0.0001), compared to BPH ones. While the expression level of PRCAT47 was increased in cancer samples, the changes were not statistically significant. In discriminating prostate tumors from BPH samples, Prcat17.3 (AUC‐ROC, 0.927) demonstrated a better diagnostic efficacy than Prcat38 (AUC‐ROC, 0.778). Moreover, real‐time RT‐PCR analyses on urine samples of prostate cancer patients revealed that prcat17.3 level is significantly elevated, (P < 0.0197; AUC‐ROC value of 0.72), compared to that of BPH patients.
Conclusion
We introduce here two novel lncRNAs with a potential application in diagnosis of prostate cancer.</description><subject>Benign</subject><subject>biomarker</subject><subject>BPH</subject><subject>Data processing</subject><subject>Genital diseases</subject><subject>Hyperplasia</subject><subject>lncRNA</subject><subject>PRCAT17.3</subject><subject>Prostate cancer</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Statistical analysis</subject><subject>Tumors</subject><subject>Urine</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kcFqFTEUhoMo9lrd-AAScCOlcz1JJneSZSnWCsWWWtdDJnNSU-Ym12SGcnfiE_iMPklznWqhC1fhJx__-c_5CXnNYMkA-PtNinnJhRTqCVkw0E0FUMunZAG8gapmotkjL3K-ASg48Odkj-tVw5TSC_Lz6jbSIYZrGmL4_eOXjb0v4vLzUT6kF8makTVLQU3oZyXUIbVxGnqKznnrMYzDlvY-2-TXPpgRaYfBXwe6SzXu9LftBtNmMNkb6lJcP_xYEyyml-SZM0PGV_fvPvl68uHq-LQ6O__46fjorLJCNqoyWqCwQqBZNY4pI2ythHWIGlGtBDKobQ8d1lJ2ncSOAdM9M1Bz7pyEldgn72bfMv_7hHls1yU2DoMJGKfc8nIuqZSQuqBvH6E3cUqhpCuUbDSAVrxQBzNly0I5oWs35QgmbVsG7a6Zdrdp-6eZAr-5t5y6Nfb_0L9VFIDNwK0fcPsfq_bi8vzLbHoHYZaakw</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Bayat, Hamid</creator><creator>Narouie, Behzad</creator><creator>Ziaee, Seyed‐Amir Mohsen</creator><creator>Mowla, Seyed Javad</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2657-5438</orcidid></search><sort><creationdate>20180801</creationdate><title>Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer</title><author>Bayat, Hamid ; Narouie, Behzad ; Ziaee, Seyed‐Amir Mohsen ; Mowla, Seyed Javad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3578-a93e3c33ea67f18a3c483cfee9ee863e104cd0be455bb5eb1019d1a0422ff5063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Benign</topic><topic>biomarker</topic><topic>BPH</topic><topic>Data processing</topic><topic>Genital diseases</topic><topic>Hyperplasia</topic><topic>lncRNA</topic><topic>PRCAT17.3</topic><topic>Prostate cancer</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Statistical analysis</topic><topic>Tumors</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayat, Hamid</creatorcontrib><creatorcontrib>Narouie, Behzad</creatorcontrib><creatorcontrib>Ziaee, Seyed‐Amir Mohsen</creatorcontrib><creatorcontrib>Mowla, Seyed Javad</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayat, Hamid</au><au>Narouie, Behzad</au><au>Ziaee, Seyed‐Amir Mohsen</au><au>Mowla, Seyed Javad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>78</volume><issue>11</issue><spage>812</spage><epage>818</epage><pages>812-818</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><abstract>Background
Long non‐coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer‐associated lncRNAs has been listed via RNA‐seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities to discriminate prostate tumors from benign prostate hyperplasia (BPH).
Methods
Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses. The expression of candidate lncRNAs was assessed by the real‐time PCR technique.
Results
Our data revealed that the expression levels of PRCAT17.3 (P < 0.0001) and PRCAT38 (P < 0.0002) were significantly upregulated in human prostate cancer tissues, compared to BPH ones. Moreover, the altered expression was much higher for PRCAT17.3 (∼2000 folds) than PRCAT38 (∼50 folds). In contrast, the expression of Cat2184.4 showed a significant down‐regulation in tumor samples (P < 0.0001), compared to BPH ones. While the expression level of PRCAT47 was increased in cancer samples, the changes were not statistically significant. In discriminating prostate tumors from BPH samples, Prcat17.3 (AUC‐ROC, 0.927) demonstrated a better diagnostic efficacy than Prcat38 (AUC‐ROC, 0.778). Moreover, real‐time RT‐PCR analyses on urine samples of prostate cancer patients revealed that prcat17.3 level is significantly elevated, (P < 0.0197; AUC‐ROC value of 0.72), compared to that of BPH patients.
Conclusion
We introduce here two novel lncRNAs with a potential application in diagnosis of prostate cancer.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29671889</pmid><doi>10.1002/pros.23538</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2657-5438</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2018-08, Vol.78 (11), p.812-818 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2027588359 |
| source | Wiley Online Library All Journals |
| subjects | Benign biomarker BPH Data processing Genital diseases Hyperplasia lncRNA PRCAT17.3 Prostate cancer Ribonucleic acid RNA Statistical analysis Tumors Urine |
| title | Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20long%20non%E2%80%90coding%20RNAs,%20Prcat17.3%20and%20Prcat38,%20could%20efficiently%20discriminate%20benign%20prostate%20hyperplasia%20from%20prostate%20cancer&rft.jtitle=The%20Prostate&rft.au=Bayat,%20Hamid&rft.date=2018-08-01&rft.volume=78&rft.issue=11&rft.spage=812&rft.epage=818&rft.pages=812-818&rft.issn=0270-4137&rft.eissn=1097-0045&rft_id=info:doi/10.1002/pros.23538&rft_dat=%3Cproquest_cross%3E2057900982%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2057900982&rft_id=info:pmid/29671889&rfr_iscdi=true |